Second Generation TKIs Will Require Survival Data to Supplant Gleevec in Front-Line CML

by Elizabeth Krutoholow

Newly approved therapeutics for chronic myelogenous leukemia (CML) or so-called second generation tyrosine kinase inhibitors (TKIs) like Ariad’s Iclusig and Pfizer’s Bosulif will require data showing survival improvements before clinicians adopt them in the front-line setting, according to Dr. Elias Jabbour, Associate Professor in the Department of Leukemia, at The University of Texas MD Anderson Cancer Center.

Read more >>> 

Bloomberg BRIEF Newsletters